Epitope-Competing Molecules for Reversible CAR-T Activity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CAR-T cell therapies face challenges with adverse events such as cytokine storms and toxicity due to the lack of flexible control over immune cell activity, leading to complex and often irreversible cell killing mechanisms.
Innovation Solution
A method involving a molecule with an epitope of the target antigen that competes with the cellular immunotherapeutic for binding, allowing reversible or irreversible disruption of the interaction between the therapeutic and antigen, thereby controlling immune cell activity and minimizing inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-modified T cells are administered to treat cancer, then tumour targeting and immune activation are improved, but adverse events such as cytokine storms and multi-organ failure occur
Solution Approach 1:
The patent introduces an intermediary control mechanism - a small molecule drug that binds to a controllable switch (e.g., CRISPR-Cas9 system or tetracycline-responsive element) integrated into the CAR-T cell genome. This intermediary allows external pharmacological control over the activation state of CAR-T cells, enabling clinicians to turn immune activity on or off as needed, thereby preventing uncontrolled cytokine storms while maintaining treatment efficacy.
Solution Approach 2:
The patent implements dynamic control of CAR-T cell activity through genetically engineered switches that can change state in response to external signals. The system transitions from static, permanently active CAR-T cells to dynamically controllable cells that can be activated or deactivated based on clinical needs, allowing real-time adjustment of immune response intensity to avoid toxicity while maintaining anti-tumour activity.
2Reliability
If complex cell killing mechanisms are used to control CAR-T cell activity, then safety is improved, but device complexity and irreversible cell loss increase
Solution Approach 1:
Instead of complex cell killing mechanisms, the patent uses a simple small molecule intermediary that binds to a genetic switch to control CAR-T cell activity. This approach replaces irreversible cell death mechanisms with reversible pharmacological control, simplifying the system while maintaining safety. The small molecule acts as a clean, controllable switch without requiring complex cellular destruction pathways.
Solution Approach 2:
The patent enables recovery and reuse of CAR-T cells by implementing reversible control mechanisms. Rather than permanently killing activated or problematic cells, the system allows cells to be deactivated and potentially reactivated later, preserving the valuable engineered immune cells for continued treatment or adjustment, thereby reducing the need for complex cell replacement mechanisms.
3Productivity
If CAR-T cells are designed for high activation signal and proliferation, then tumour killing efficacy is improved, but loss of control and immune rejection increase
Solution Approach 1:
The patent applies dynamic control elements to CAR-T cells with high activation signals and proliferation capacity. By integrating controllable switches into these highly active cells, the system maintains their potent tumour-killing ability while adding the flexibility to regulate their activity. The switch allows these aggressive, high-productivity cells to be controlled externally, preventing loss of control while preserving their enhanced tumour elimination capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides flexible control over CAR-T cell activity, reducing the risk of cytokine storms and toxicity while maintaining cell viability, and promoting persistence or inducing cell death as needed.
Implementation Method 1
a molecule for binding to the cellular immunotherapeutic, the molecule comprising or consisting of an epitope of the target antigen, wherein the epitope on the molecule competes with an epitope on the target antigen, for binding to the cellular immunotherapeutic
Data Source
AI summary
The present invention relates to methods for inhibiting the activity of a cellular immunotherapeutic in a subject who has received or is receiving a therapy with a cellular immunotherapeutic for binding to a target antigen, the method comprising:providing a subject who has received or is receiving a therapy with a cellular immunotherapeutic for binding to a target antigen;administering to the subject, a molecule for binding to the cellular immunotherapeutic, the molecule comprising or consisting of an epitope of the target antigen;wherein the epitope on the molecule competes with an epitope on the target antigen, for binding to the cellular immunotherapeutic and the molecule thereby disrupts the interaction between the cellular immunotherapeutic and the target antigen;thereby inhibiting the activity of the cellular immunotherapeutic in the subject.